NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer

叶黄素 医学 奥沙利铂 吉西他滨 伊立替康 肿瘤科 内科学 临床试验 胰腺癌 氟尿嘧啶 无进展生存期 结直肠癌 癌症 化疗
作者
Federico Nichetti,Simone Rota,Paolo Ambrosini,Chiara Pircher,Eleonora Gusmaroli,Michele Droz dit Busset,Sara Pusceddu,Carlo Sposito,Jorgelina Coppa,Federica Morano,Filippo Pietrantonio,Maria Di Bartolomeo,Luigi Mariani,Vincenzo Mazzaferro,Filippo de Braud,Monica Niger
出处
期刊:JAMA network open [American Medical Association]
卷期号:7 (1): e2350756-e2350756 被引量:16
标识
DOI:10.1001/jamanetworkopen.2023.50756
摘要

Importance The NAPOLI 3 trial showed the superiority of fluorouracil, leucovorin, liposomal irinotecan, and oxaliplatin (NALIRIFOX) over the combination of gemcitabine and nab-paclitaxel (GEM-NABP) as first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC). Analyses comparing NALIRIFOX and GEM-NABP with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) have not yet been reported. Objective To derive survival, response, and toxic effects data from phase 3 clinical trials and compare NALIRIFOX, FOLFIRINOX, and GEM-NABP. Data Sources After a systematic search of PubMed, Scopus, Embase, and American Society of Clinical Oncology and European Society for Medical Oncology meetings’ libraries, Kaplan-Meier curves were extracted from phase 3 clinical trials conducted from January 1, 2011, until September 12, 2023. Study Selection Phase 3 clinical trials that tested NALIRIFOX, FOLFIRINOX, or GEM-NABP as first-line treatment of metastatic PDAC and reported overall survival (OS) and progression-free survival (PFS) curves were selected. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses of Individual Participant Data reporting guidelines. Data Extraction And Synthesis Individual patient OS and PFS data were extracted from Kaplan-Meier plots of original trials via a graphic reconstructive algorithm. Overall response rates (ORRs) and grade 3 or higher toxic effects rates were also collected. A pooled analysis was conducted, and results were validated via a network meta-analysis. Main Outcomes and Measures The primary end point was OS. Secondary outcomes included PFS, ORR, and toxic effects rates. Results A total of 7 trials with data on 2581 patients were analyzed, including 383 patients treated with NALIRIFOX, 433 patients treated with FOLFIRINOX, and 1756 patients treated with GEM-NABP. Median PFS was longer in patients treated with NALIRIFOX (7.4 [95% CI, 6.1-7.7] months) or FOLFIRINOX (7.3 [95% CI, 6.5-7.9] months; [HR], 1.21 [95% CI, 0.86-1.70]; P = .28) compared with patients treated with GEM-NABP (5.7 [95% CI, 5.6-6.1] months; HR vs NALIRIFOX, 1.45 [95% CI, 1.22-1.73]; P < .001). Similarly, GEM-NABP was associated with poorer OS (10.4 [95% CI, 9.8-10.8]; months) compared with NALIRIFOX (HR, 1.18 [95% CI, 1.00-1.39]; P = .05], while no difference was observed between FOLFIRINOX (11.7 [95% CI, 10.4-13.0] months) and NALIRIFOX (11.1 [95% CI, 10.1-12.3] months; HR, 1.06 [95% CI, 0.81-1.39]; P = .65). There were no statistically significant differences in ORR among NALIRIFOX (41.8%), FOLFIRINOX (31.6%), and GEM-NABP (35.0%). NALIRIFOX was associated with lower incidence of grade 3 or higher hematological toxic effects (eg, platelet count decreased 1.6% vs 11.8% with FOLFIRINOX and 10.8% with GEM-NABP), but higher rates of severe diarrhea compared with GEM-NABP (20.3% vs 15.7%). Conclusions and Relevance In this systematic review and meta-analysis, NALIRIFOX and FOLFIRINOX were associated with similar PFS and OS as first-line treatment of advanced PDAC, although NALIRIFOX was associated with a different toxicity profile. Careful patient selection, financial toxic effects consideration, and direct comparison between FOLFIRINOX and NALIRIFOX are warranted.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
深爱不疑发布了新的文献求助10
1秒前
jennie完成签到 ,获得积分10
1秒前
徐徐发布了新的文献求助80
1秒前
不信慕斯完成签到,获得积分10
1秒前
Jokeypu完成签到,获得积分10
1秒前
gnr2000发布了新的文献求助30
2秒前
2秒前
song99完成签到,获得积分10
2秒前
清醒的ZY发布了新的文献求助50
2秒前
二小发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
澹台灭明发布了新的文献求助10
3秒前
3秒前
bkagyin应助AteeqBaloch采纳,获得10
4秒前
二二二发布了新的文献求助10
4秒前
万能图书馆应助LIU采纳,获得10
4秒前
绿麦盲区发布了新的文献求助10
4秒前
FIGGIEKIO完成签到,获得积分10
4秒前
星星发布了新的文献求助10
4秒前
852应助luoshi采纳,获得10
5秒前
小王发布了新的文献求助10
5秒前
hahah完成签到,获得积分10
5秒前
5秒前
yang完成签到 ,获得积分10
6秒前
lynn_zhang完成签到,获得积分10
6秒前
化学狗发布了新的文献求助10
7秒前
7秒前
浩浩完成签到,获得积分10
8秒前
胡图图完成签到,获得积分10
8秒前
包容的剑发布了新的文献求助10
9秒前
10秒前
小马甲应助细腻沅采纳,获得10
10秒前
11秒前
招财不肥完成签到,获得积分10
11秒前
11秒前
77完成签到,获得积分10
12秒前
NexusExplorer应助顾阿秀采纳,获得10
12秒前
12秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762